Terapevticheskii arkhiv Terapevticheskii arkhiv Терапевтический архив 0040-3660 2309-5342 LLC Obyedinennaya Redaktsiya 33407 Editorial article Передовая статья Improved prognosis of generalized AL-amyloidosis ina patient with multiple myeloma treated according to theVAD scheme УЛУЧШЕНИЕ ПРОГНОЗА ГЕНЕРАЛИЗОВАННОГО AL-АМИЛОИДОЗА У ПАЦИЕНТАС МНОЖЕСТВЕННОЙ МИЕЛОМОИ ПРИ ЛЕЧЕНИИ ПО СХЕМЕ VAD Sarkisova I A Саркисова И А ММА им. И. М. Сеченова
Rameev V V Рамеев В В ММА им. И. М. Сеченова
Kozlovskaya L V Козловская Л В ММА им. И. М. Сеченова
Andreeva N E Андреева Н Е Больница МПС № 2, Москва
ММА им. И. М. Сеченова Больница МПС № 2, Москва 15 08 2003 78 8 NO8 (2003) Том 78, №8 (2003) 81 83 13 04 2020 Copyright ©; 2003, Consilium Medicum Copyright ©; 2003, ООО "Консилиум Медикум" 2003 Consilium Medicum ООО "Консилиум Медикум" https://creativecommons.org/licenses/by-nc-sa/4.0 https://ter-arkhiv.ru/0040-3660/article/view/33407
multiple myeloma generalized amyloidosis treatment prognosis множественная миелома генерализованный амилоидоз лечение прогноз 1. Тареева И. Е. (ред.) Нефрология. Руководство для врачей. М.; 2000. 2. Dubrey S. W., Cha К., Anderson J. et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Quart. J. Med. 1998; 91 (2): 141-157. 3. Reisinger J., Dubrey S. W., Lavalley M. et al. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. Am. Coll. Cardiol. 1997; 30 (4): 1046-1051. 4. Falk R. H., Plehn J. F., Deering T. et al. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis.Am. J. Cardiol. 1987; 59 (5): 418-422. 5. Dubrey S. W., Bilazarian S., LaVatley M. et al. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am. Heart J. 1997; 134 (6): 994-1001. 6. Falk R. H., Skinner M. The systemic amyloidosis: an overview. Advanc. Intern. Med. 2000; 45: chapt. 4. 7. Ropper A., Gorson K. Current concepts: Neuropathies associated with paraproteinemia. N. Engl. J. Med. 1998; 338: 1601- 1607. 8. Falk R. H., Comenzo R. L., Skinner M. The systemic amyloidosis. Ibid. 1997; 1: 898-909. 9. Kyle R. A., Gertz M. A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin. Hematol. 1995; 32: 45-59. 10. Tada S., lida M., Yao T. et al. Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein. Gut 1993; 34 (10): 1412-1417. 11. Kitchens C. S. The anatomic basis of purpura. Progr. Hemostas. Thrombos. 1980; 5: 211-244. 12. Sezer O., Eucker J., Schmid P., P ossinger K. New therapeutic approaches in primary systemic AL amyloidosis. Ann. Hematol. 2000; 79: 1-6. 13. Kyle R. A., Greipp P. R. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood 1978; 52: 818-827. 14. Kyle R. A., Gertz M. A., Greipp P. R. et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.N. Engl. J. Med. 1997; 336: 1202-1207. 15. Comenzo R. L., Vosburgh E., Falk R. H. et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91 (10): 3662-3670. 16. Van E. K., Zachee P., Maertens J. et. al. Treatment of primary amyloidosis with VAD combination chemotherapy results in improved survival. Ibid. 1996; 88: 591. 17. Schena P. P., Pannarale G., Carbonara M. C. Clinical and therapeutic aspects of renal amyloidosis. Nephrol. Dial. Transplant. 1996; 1(9): 63-86.